HIV Infections
Conditions
Keywords
First-time-in-human, GSK4524184, Healthy volunteers, Multiple Ascending Dose, Single Ascending Dose, VH4524184
Brief summary
This study is designed to investigate the safety, tolerability and PK of VH4524184 (GSK4524184) and the potential of VH4524184 to inhibit or induce CYP3A activity in healthy participants.
Interventions
DRUGVH4524184
VH4524184 will be administered.
DRUGMidazolam
Midazolam will be administered in the highest dose cohort in Part 2 (Cohorts 8 or 9).
DRUGPlacebo
Placebo will be administered.
Sponsors
ViiV Healthcare
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
This will be a double blind study.
Intervention model description
Participants will receive escalating doses of VH4524184 or placebo in Part 1 and Part 2 of the study. In Part 3, participants will receive VH4524184 under fasted and fed conditions.
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Participant must be 18 to 50 years of age. * Participants who are overtly healthy. * Body weight \>=50.0 kilograms (kg) (110 pounds \[lbs\]) for men and \>=45.0 kg (99 lbs) for women and body mass index within the range 18.5 to 32.0 kilograms per meter square (kg/m\^2) (inclusive). * Male or female. Male Participants: No contraceptive restrictions for male participants. Female Participants: A female participant (female sex assigned at birth) is eligible to participate if she is not pregnant, or breastfeeding and is not physically able to have a baby.
Exclusion criteria
* History or presence of clinical condition that could significantly alter how medicines are absorbed, broken down or eliminated from the body; be risky to the participant, or make it difficult to interpret the data from the study. * Pre-existing clinically relevant gastro-intestinal disorders. * Abnormal blood pressure. * Certain blood or other cancers within the past 5 years. * Breast cancer within the past 10 years * Current or chronic history of liver disease or liver or bile tract abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). * QT interval corrected for heart rate according to Fridericia's formula (QTcF) \>450 milliseconds (msec). * Medical history of cardiac arrhythmias or cardiac disease or a family and personal history of long QT syndrome. * History of seizure * Any known or suspected pre-existing psychiatric condition, including depression, anxiety and insomnia/sleep disturbances. * Any positive (abnormal) response to the Columbia Suicide Severity Rating Scale (CSSRS). * Past or intended use of over-the-counter or prescription medication within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to dosing and for the duration of the study. * Receipt of any live vaccine(s) or vaccines against Coronavirus disease 2019 (Covid-19) within 28 days prior to screening or plans to receive such vaccines during the study. * Exposure to more than 4 new investigational products (including long-acting investigational products) within 12 months prior to the first dosing day. * Current enrollment or past participation in another investigational study in which an investigational intervention (e.g., drug, human blood product, monoclonal antibody, vaccine, invasive device) was administered within the last 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer) before signing of consent (OR screening) any other clinical study. * Participation in the study would result in loss of blood or blood products in excess of 500 milliliters (mL) over a 56-day period. * Current enrollment or past participation in this clinical study. * Estimated Glomerular Filtration Rate (eGFR) \<90 milliliters per minute (mL/min) (calculated using Chronic Kidney Disease Epidemiology Collaboration equation) or serum creatinine \>1.1 times Upper limit of normal (ULN). * Hemoglobin \<12.5 grams per deciliter (g/dL) for men and \<11 g/dL for women * ALT or AST \>1.5 times ULN * Total bilirubin \>1.5 times ULN (isolated bilirubin \>1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent \[%\]). * Any significant arrhythmia or Electrocardiogram (ECG) finding *
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Part 2: T1/2 following dosing of VH4524184 | Up to 6.5 weeks |
| Part 1: Time to maximum observed plasma drug concentration (tmax) following dosing of VH4524184 | Up to 4 weeks |
| Part 2: Tmax following dosing of VH4524184 | Up to 6.5 weeks |
| Part 1: Apparent terminal half-life (t1/2) following dosing of VH4524184 | Up to 4 weeks |
| Part 1: Number of participants with serious adverse events (SAE) and non-serious adverse events (non-SAE) | Up to 4 weeks |
| Part 2: Number of participants with SAE and non-SAE | Up to 6.5 weeks |
| Part 3: Number of participants with SAE and non-SAE | Up to 6.5 weeks |
| Part 1: Number of participants with adverse events based on severity | Up to 4 weeks |
| Part 2: Number of participants with adverse events by severity | Up to 6.5 weeks |
| Part 3: Number of participants with adverse events based on severity | Up to 6.5 weeks |
| Part 1: Percentage of participants who discontinue treatment due to adverse events (AE) | Up to 4 weeks |
| Part 2: Percentage of participants who discontinue treatment due to AE | Up to 6.5 weeks |
| Part 3: Percentage of participants who discontinue treatment due to AE | Up to 6.5 weeks |
| Part 1: Change from Baseline in Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) and Alkaline phosphatase (ALP) (International units per liter) | Baseline (Day 1) and up to 4 weeks |
| Part 2: Change from Baseline in AST, ALT and ALP (International units per liter) | Baseline (Day 1) and up to 6.5 weeks |
| Part 3: Change from Baseline in AST, ALT and ALP (International units per liter) | Baseline (Day 1) and up to 6.5 weeks |
| Part 1: Change from Baseline in Total bilirubin and Direct bilirubin (Micromoles per liter) | Baseline (Day 1) and up to 4 weeks |
| Part 2: Change from Baseline in Total bilirubin and Direct bilirubin (Micromoles per liter) | Baseline (Day 1) and up to 6.5 weeks |
| Part 3: Change from Baseline in Total bilirubin and Direct bilirubin (Micromoles per liter) | Baseline (Day 1) and up to 6.5 weeks |
| Part 1: Change from Baseline in Prothrombin time and Partial Thromboplastin Time (Seconds) | Baseline (Day 1) and up to 4 weeks |
| Part 2: Change from Baseline in Prothrombin time and Partial Thromboplastin Time (Seconds) | Baseline (Day 1) and up to 6.5 weeks |
| Part 3: Change from Baseline in Prothrombin time and Partial Thromboplastin Time (Seconds) | Baseline (Day 1) and up to 6.5 weeks |
| Part 1: Change from Baseline in International normalized ratio (INR) (Ratio) | Baseline (Day 1) and up to 4 weeks |
| Part 2: Change from Baseline in INR (Ratio) | Baseline (Day 1) and up to 6.5 weeks |
| Part 3: Change from Baseline in INR (Ratio) | Baseline (Day 1) and up to 6.5 weeks |
| Part 1: Number of participants with maximum toxicity grade increase from Baseline in liver panel laboratory parameters; AST, ALT, ALP, Total bilirubin, Direct bilirubin, Prothrombin time, Partial Thromboplastin Time and INR | Baseline (Day 1) and up to 4 weeks |
| Part 2: Number of participants with maximum toxicity grade increase from Baseline in liver panel laboratory parameters; AST, ALT, ALP, Total bilirubin, Direct bilirubin, Prothrombin time, Partial Thromboplastin Time and INR | Baseline (Day 1) and up to 6.5 weeks |
| Part 3: Number of participant with maximum toxicity grade increase from Baseline in liver panel laboratory parameters; AST, ALT, ALP, Total bilirubin, Direct bilirubin, Prothrombin time, Partial Thromboplastin Time and INR | Baseline (Day 1) and up to 6.5 weeks |
| Part 1: Area under the plasma-concentration time curve from zero (pre-dose) extrapolated to infinite time (AUC[0-infinity]) following dosing of VH4524184 | Up to 4 weeks |
| Part 2: Area under the plasma concentration-time curve from zero (pre-dose) to the end of the dosing interval at steady state (AUC[0-tau]) following dosing of VH4524184 | Up to 6.5 weeks |
| Part 1: Maximum observed plasma drug concentration (Cmax) following dosing of VH4524184 | Up to 4 weeks |
| Part 2: Cmax following dosing of VH4524184 | Up to 6.5 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Part 2: Number of participants with treatment emergent Grade 3 or Grade 4 laboratory abnormalities | Up to 6.5 weeks |
| Part 3: Number of participants with treatment emergent Grade 3 or Grade 4 laboratory abnormalities | Up to 6.5 weeks |
| Part 1: Number of participants with treatment emergent Grade 3 or Grade 4 laboratory abnormalities | Up to 4 weeks |
Countries
United States
Outcome results
None listed